Therapierelevante unterschiede bei betablockern und ACE-hemmern: Innovation oder plagiat?

P. Dominiak*, A. Dendorfer, W. Raasch

*Korrespondierende/r Autor/-in für diese Arbeit
1 Zitat (Scopus)

Abstract

As exemplified by the two classes of substance beta blockers and ACE inhibitors, the question is considered as to when new developments within a drug family can be termed innovations and when they must be seen purely as plagiarisms ("me-too" preparations). It is noted that in principle no innovations are to be expected from generics, since these substances are are not the subject of specific research. Although large-scale clinical studies in recent years have identified a new indication - cardiac insufficiency - for the beta blockers metoprolol, bisoprolol and carvedilol, this must not be considered an innovation in the sense of a new development. The translatability of the study results to uninvestigated substances is uncertain. In contrast to the beta blockers, the indications for the ACE inhibitors have long been known, but again, the new generic preparations that have come onto the market are not innovations.
Titel in ÜbersetzungTherapy-relevant differences among beta blockers and ACE inhibitors - Innovation or plagiarism?
OriginalspracheDeutsch
ZeitschriftMMW-Fortschritte der Medizin
Jahrgang144
Ausgabenummer1-2
Seiten (von - bis)50-54
Seitenumfang5
ISSN1438-3276
PublikationsstatusVeröffentlicht - 17.01.2002

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Therapierelevante unterschiede bei betablockern und ACE-hemmern: Innovation oder plagiat?“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren